JOP20250041A1 - أجسام مضادة وشظايا جسم مضاد موُجَّهة ضد أحادي ميثيل أوريستاتين - Google Patents

أجسام مضادة وشظايا جسم مضاد موُجَّهة ضد أحادي ميثيل أوريستاتين

Info

Publication number
JOP20250041A1
JOP20250041A1 JOJO/P/2025/0041A JOP20250041A JOP20250041A1 JO P20250041 A1 JOP20250041 A1 JO P20250041A1 JO P20250041 A JOP20250041 A JO P20250041A JO P20250041 A1 JOP20250041 A1 JO P20250041A1
Authority
JO
Jordan
Prior art keywords
antibodies
antibody fragments
adc
monomethyl auristatin
payload
Prior art date
Application number
JOJO/P/2025/0041A
Other languages
English (en)
Inventor
M Bordreau Brandon
Duc NGUYEN Toan
P Balthasar Joseph
Ryan Polli Joseph
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of JOP20250041A1 publication Critical patent/JOP20250041A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

يتعلق هذا الكشف بتركيبات وطرق لتقليل سمية غير مستهدفة لمترافقات الجسم المضاد والدواء antibody-drug conjugates (ADCs). تشتمل التركيبات على مركب الجسم المضاد والدواء antibody-drug conjugates ADC، وعامل مُستهدِف للدواء (حمولة) يتم توصيله بواسطة مركب الجسم المضاد والدواء antibody-drug conjugates ADC أو مشتق من الجسم المضاد والدواء antibody-drug conjugates ADC. يمكن توصيل مركب الجسم المضاد والدواء antibody-drug conjugates ADC والعامل المُستهدِف للحمولة معًا أو بشكل منفصل في معالجة حالات مختلفة (مثل الأورام) بواسطة مركب الجسم المضاد والدواء antibody-drug conjugates ADC. تتضمن أمثلة العوامل المُستهدِفة للحمولة أجسام مضادة، شظايا، أو تعديلات منها.صورة (1)
JOJO/P/2025/0041A 2022-08-24 2025-02-24 أجسام مضادة وشظايا جسم مضاد موُجَّهة ضد أحادي ميثيل أوريستاتين JOP20250041A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263373367P 2022-08-24 2022-08-24
US202363520689P 2023-08-21 2023-08-21
PCT/US2023/072852 WO2024044709A2 (en) 2022-08-24 2023-08-24 Anti-monomethyl auristatin antibodies and antibody fragments

Publications (1)

Publication Number Publication Date
JOP20250041A1 true JOP20250041A1 (ar) 2025-02-24

Family

ID=90014109

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2025/0041A JOP20250041A1 (ar) 2022-08-24 2025-02-24 أجسام مضادة وشظايا جسم مضاد موُجَّهة ضد أحادي ميثيل أوريستاتين

Country Status (15)

Country Link
EP (1) EP4577568A2 (ar)
JP (1) JP2025528390A (ar)
KR (1) KR20250060232A (ar)
CN (1) CN120035610A (ar)
AU (1) AU2023329378A1 (ar)
CA (1) CA3265572A1 (ar)
CO (1) CO2025002048A2 (ar)
CR (1) CR20250060A (ar)
DO (1) DOP2025000040A (ar)
GE (1) GEAP202516711A (ar)
IL (1) IL319054A (ar)
JO (1) JOP20250041A1 (ar)
MX (1) MX2025002127A (ar)
PE (1) PE20251523A1 (ar)
WO (1) WO2024044709A2 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025043019A1 (en) * 2023-08-21 2025-02-27 The Research Foundation For The State University Of New York Slc4a1 (band 3) binding single domain antibodies for increased blood retention
EP4725508A1 (en) 2024-06-05 2026-04-15 RemeGen Co., Ltd. Ligand-drug conjugate having free payload recovery unit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
KR102367658B1 (ko) * 2017-03-29 2022-02-25 타이페이 메디컬 유니이버시티 항원 특이적 t 세포 및 그의 용도
KR102508933B1 (ko) * 2017-11-17 2023-03-13 에이비엘바이오 주식회사 알파-시누클레인에 대한 항체 및 그 용도
CN109912684A (zh) * 2019-03-08 2019-06-21 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体
US20230071019A1 (en) * 2019-12-04 2023-03-09 The Research Foundation For The State University Of New York Compositions and methods for reducing off-target toxicity of antibody drug conjugates

Also Published As

Publication number Publication date
CO2025002048A2 (es) 2025-07-17
CN120035610A (zh) 2025-05-23
DOP2025000040A (es) 2025-06-15
JP2025528390A (ja) 2025-08-28
GEAP202516711A (en) 2025-06-10
WO2024044709A2 (en) 2024-02-29
CA3265572A1 (en) 2024-02-29
PE20251523A1 (es) 2025-06-05
WO2024044709A3 (en) 2024-04-04
IL319054A (en) 2025-04-01
MX2025002127A (es) 2025-05-02
AU2023329378A1 (en) 2025-03-06
KR20250060232A (ko) 2025-05-07
EP4577568A2 (en) 2025-07-02
CR20250060A (es) 2025-03-18

Similar Documents

Publication Publication Date Title
JOP20250041A1 (ar) أجسام مضادة وشظايا جسم مضاد موُجَّهة ضد أحادي ميثيل أوريستاتين
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2023004032A (es) Terapias inmuno-oncologicas con conjugados de il-2.
MX2022013768A (es) Conjugados anticuerpo-fármaco (adc) que comprenden un anticuerpo anti-trop-2, composiciones que comprenden dichos adc, así como métodos para fabricar y utilizar los mismos.
SA523442921B1 (ar) جزيئات ربط علاجية
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
CR20240415A (es) MOLÉCULAS DE UNIÓN CONTRA FRa
MX2024011775A (es) Conjugados de farmaco-anticuerpo dirigidos al receptor de folato alfa y metodos de uso
EP4295917A3 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
MX2025002235A (es) Conjugados de farmacos anticuerpo anti-sez6
NZ805366A (en) Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap)
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
WO2024163641A3 (en) Formulations for treating cancer
MX2025004144A (es) Anticuerpo anti-gucy2c y usos del mismo
MX2025014033A (es) Anticuerpos y sus conjugados de anticuerpo y farmaco
MX2025009383A (es) Anticuerpos anti antigeno de membrana especifico de prostata (psma), conjugados y metodos de uso
WO2023009751A3 (en) Antibodies and antibody conjugates specific for nectin-4 and methods of use thereof
ZA202209925B (en) Compositions and methods for treating pompe disease
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine
MX2025015337A (es) Anticuerpos de nectina-4 y conjugados anticuerpo-farmaco
WO2025078881A3 (en) Anti-claudin 18.2 antibody drug conjugates comprising topoisomerase i inhibitor and uses thereof
TW202617781A (zh) Ｎｅｃｔｉｎ－４抗體及抗體藥物結合物
TW202615007A (zh) 化合物、組成物和方法
MX2025011751A (es) Conjugados anticuerpo-farmaco de derivados de camptotecina y usos de estos